Connection

Co-Authors

This is a "connection" page, showing publications co-authored by PATRICIA TRONCOSO and BRIAN FRANCIS CHAPIN.
Connection Strength

1.811
  1. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis. 2018 06; 21(2):221-227.
    View in: PubMed
    Score: 0.611
  2. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urol Oncol. 2024 04; 42(4):116.e1-116.e7.
    View in: PubMed
    Score: 0.233
  3. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306.
    View in: PubMed
    Score: 0.188
  4. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673.
    View in: PubMed
    Score: 0.181
  5. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178.
    View in: PubMed
    Score: 0.172
  6. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res. 2024 Nov 09; 12(1):134.
    View in: PubMed
    Score: 0.062
  7. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024 Sep; 134(3):449-458.
    View in: PubMed
    Score: 0.060
  8. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3).
    View in: PubMed
    Score: 0.055
  9. Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology. 2022 04; 303(1):110-118.
    View in: PubMed
    Score: 0.051
  10. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).
    View in: PubMed
    Score: 0.045
  11. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97.
    View in: PubMed
    Score: 0.044
  12. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. BJU Int. 2018 07; 122(1):66-75.
    View in: PubMed
    Score: 0.039
  13. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76.
    View in: PubMed
    Score: 0.037
  14. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.